Latest Breaking News On - Inflection biosciences - Page 1 : comparemela.com

Anavo Therapeutics Strengthens Management Team

Anavo Therapeutics Strengthens Management Team
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Baden wübergUnited statesUnited kingdomBirgit zechAnna quattropaniShaun mcnultyAwakn life sciencesUniversity of genevaMerck kgaaUniversity of cambridgeMerck kgaUniversity of yorkUniversity of californiaClinical developmentVentures fundChief scientific officer

Lupus Nephritis Pipeline Drugs Analysis Report (2023 Updates): FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | Roche, Equillium, BeiGene, Janssen Research & Development, Horizon Therapeutics, Novartis, Roche, AstraZeneca |

Lupus Nephritis Pipeline Drugs Analysis Report (2023 Updates): FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | Roche, Equillium, BeiGene, Janssen Research & Development, Horizon Therapeutics, Novartis, Roche, AstraZeneca |
medgadget.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medgadget.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomSaphnelo anifrolumabBristol myers squibbGaurav boraLas vegasCorestem incHealthcare consulting servicesKezar life sciencesLupus nephritis key companiesAlexion pharmaceuticalsConsulting servicesUser hospitals and ambulatory surgical centersMarket researchKey lupus nephritis companiesNovartis pharmaceuticals

Mysthera Therapeutics Launches to Develop First-in-Class Autoimmune Disease Therapies

Mysthera Therapeutics AG, a company developing first-in-class, oral therapeutics to treat complex autoimmune diseases, launched today with $3.5 million seed capital from founding investor Forty51 Ventures. The capital will be used to advance its portfolio of pre-clinical stage, pan-PIM kinase inhibitors to uniquely modulate multi-lineage immune cell functions.

Stefan haakDarren cunninghamInflection biosciences ltdChief executive officerInflection biosciencesMysthera therapeuticsAutoimmune diseasesForty51 venturesDarren cunninghamKinase inhibitorsImmune cellDisease severity

Irish drug developer signs licensing deal for autoimmune therapies

Inflection Biosciences chief Darren Cunningham will be head of Swiss-based Mysthera Therapeutics

Darren cunninghamMichael oneillInflection biosciencesChief executive officerMichaelo neillMysthera therapeutics

Mysthera Therapeutics Raises $3 5M in Seed Funding

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

Darren cunninghamStefan haakInflection biosciences ltdMysthera therapeuticsInflection biosciences